News Spotlight: Biofrontera AG (NASDAQ:BFRA)

Biofrontera AG (NASDAQ:BFRA)  changed 3.00% to recent value of $10.65. The stock transacted 172 shares during most recent day however it has an average volume of 0.94K shares. It spotted trading -41.87% off 52-week high price. On the other end, the stock has been noted 18.33% away from the low price over the last 52-weeks.

On Jan. 10, 2020, Biofrontera AG (NASDAQ:BFRA) an international biopharmaceutical company,  disclosed its results for the first nine months ended September 30, 2019. At the same time, the guidance for fiscal 2019 has been adjusted.

The preliminary, unaudited turnover of the Biofrontera Group for the period 1 January to 31 December 2019 was between 31.1 and 31.4 million euros, slightly above the last guidance. This corresponds to a sales growth of almost 50% compared to the previous year, with pure product sales increasing by approximately 46%.

Preliminary revenues from product sales in the USA are expected to be around EUR 23.3 million, compared to EUR 14.9 million in the same period of 2018 (ca. +57%). In Germany, revenues from product sales will amount to approx. EUR 4.6 million, compared with EUR 3.3 million for the full year 2018 (ca. +40%). Revenues for Europe excluding Germany were roughly on par with the previous year, with rising revenues in Spain and the United Kingdom offsetting lower revenues with license partners.

Sales in the fourth quarter amounted to approximately EUR 12.2 million, compared to EUR 6.6 million in the previous year. Biofrontera thus achieved the highest quarterly sales in its corporate history. Decisive for the strong growth was again the steadily growing US business, as well as the sales increases in Germany and Spain. The latter were mainly due to the European approval for Ameluz® in combination with daylight PDT. Due to a price increase of about 6% for Ameluz® in the USA effective January 1, 2020, the product was in some practices stocked up in December 2019, also contributing to the strong sales growth in the last quarter.

Its earnings per share (EPS) expected to touch remained 72.30% for this year .

 The company has 22.42M of outstanding shares and 10.31M shares were floated in the market.  The price moved ahead of 0.28% from the mean of 20 days, -22.90% from mean of 50 days SMA and performed -21.59% from mean of 200 days price. Company’s performance for the week was 5.04%, -16.21% for month and YTD performance remained 3.00%.

Leave a Reply

Your email address will not be published. Required fields are marked *